“…The human ether‐a‐go‐go‐related gene (hERG), which is highly expressed in heart tissue, is closely connected to the occurrence of cardiotoxicity (Didziapetris & Lanevskij, ; Schyman, Liu, & Wallqvist, ; Wang, Sun, et al, ). The blockade of hERG may cause long QT syndrome and Torsade de Pointes, which lead to palpitations, fainting, or even sudden death (Schyman et al, ) such as astemizole, terfenadine, cisapride, sertindole, terolidine, droperidol, lidoflazine, and grepafloxacin (Braga et al, ; Su, Tu, Esposito, & Tseng, ). Therefore, it is essential to ensure that the drug would not cause blockade of the hERG function before entering into the market.…”